<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002539</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-80931</org_study_id>
    <secondary_id>EOI-80931</secondary_id>
    <secondary_id>EORTC-80931</secondary_id>
    <secondary_id>MRC-BO06</secondary_id>
    <secondary_id>EU-93024</secondary_id>
    <nct_id>NCT00002539</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma</brief_title>
  <official_title>A RANDOMISED TRIAL OF CHEMOTHERAPY WITH OR WITHOUT GRANULOCYTE COLONY-STIMULATING FACTOR IN OPERABLE OSTEOSARCOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of
      immune cells found in bone marrow or peripheral blood and may help a person's immune system
      recover from the side effects of chemotherapy. It is not yet known whether chemotherapy and
      surgery plus G-CSF is more effective than chemotherapy and surgery alone in treating patients
      with osteosarcoma.

      PURPOSE: Randomized phase III trial to compare the effectiveness combination chemotherapy and
      surgery with or without G-CSF in treating patients who have newly diagnosed osteosarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the overall and disease-free survival of patients with newly diagnosed
           osteosarcoma of the extremity treated with conventional vs intensive cisplatin and
           doxorubicin with or without filgrastim (G-CSF) before and after definitive surgery.

        -  Compare the toxicity of these regimens in these patients.

        -  Compare the response in patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment
      arms.

        -  Arm I: Patients receive conventional doxorubicin (DOX) IV over 4 hours on days 1-3 and
           cisplatin (CDDP) IV continuously on day 1. Treatment continues every 3 weeks for 2
           courses. At week 6, patients undergo amputation or local resection based on pretherapy
           imaging and response to chemotherapy. Beginning 2 weeks after surgery, patients receive
           4 additional courses of conventional chemotherapy.

        -  Arm II: Patients receive intensive DOX and CDDP as above on day 1 plus filgrastim
           (G-CSF) subcutaneously on days 4-13. Treatment continues every 2 weeks for 3 courses. At
           week 6, patients undergo definitive surgery as in arm I. Beginning 2 weeks after
           surgery, patients receive 3 additional courses of intensive DOX and CDDP with G-CSF.

      Patients who experience disease progression during preoperative chemotherapy undergo surgery
      earlier than scheduled and complete all scheduled chemotherapy (6 courses) after surgery, at
      the discretion of the surgeon and oncologist. Within 4 weeks after limb-sparing procedure,
      patients with inadequate margins undergo amputation, followed 2 weeks later by chemotherapy.

      Patients are followed monthly for 6 months, every 2 months for 6 months, every 3 months for 1
      year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1993</start_date>
  <primary_completion_date type="Actual">October 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">214</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven resectable osteosarcoma of the long bone of an extremity

          -  No parosteal (juxtacortical), periosteal, Pagetoid, or post-irradiation sarcoma

          -  No distant metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  40 and under

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Neutrophil count at least 1,500/mm^3 OR

          -  WBC at least 3,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.2 mg/dL

        Renal:

          -  Glomerular filtration rate at least 60 mL/min

        Cardiovascular:

          -  No history of cardiac dysfunction

        Other:

          -  No other prior or concurrent malignancy except basal cell skin cancer OR

          -  Carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

        Surgery:

          -  See Disease Characteristics

        Other:

          -  No prior therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne A. Nooij, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian J. Lewis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leeds Cancer Centre at St. James's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels (Bruxelles)</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels (Bruxelles)</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Kommunehospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emma Kinderziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>NL-1100 DE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Francisco Gentil-Centro de Lisboa</name>
      <address>
        <city>Lisbon</city>
        <zip>1099-023 Codex</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital and Research Centre</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology, Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>Sl-1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Saudi Arabia</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007 Jan 17;99(2):112-28.</citation>
    <PMID>17227995</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewis IJ, Nooij M: Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: a randomised controlled trial conducted by the European Osteo Sarcoma Intergroup (ISRCTN 86294690). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-3281, 816, 2003.</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

